Once-a-day treatment with oral ANVS401 was found to significantly improve motor skills among Parkinson’s disease patients in a Phase 2a clinical trial. Annovis Bio, the company developing ANVS401, is now planning to meet with the U.S. Food and Drug Administration (FDA) to discuss possibly initiating larger Phase 3 studies. “We are thrilled by these improvements in motor […]

Cartesian Therapeutics focuses on RNA-based cell therapies. In August, for example, the company announced successful results from a Phase I trial of an RNA-based treatment called Descartes-08 for the autoimmune disorder myasthenia gravis. Murat Kalayoglu, MD, PhD, president and CEO describes this treatment as “an autologous T-cell product engineered with RNA to express a chimeric […]

To help celebrate GEN’s 40th Anniversary with this special October issue, we asked scientists and business professionals in academia and industry to give us their reflections, impressions, and insights on the biotechnology industry and the life sciences. We also queried them on what they believe the future might look like for biotechnology. We sought the thoughts […]